Quantcast

GranuFlo Lawsuits Mount, as Bernstein Liebhard LLP Notes Filing of New Dialysis Lawsuit Against Fresenius Medical Care in Texas

January 24, 2014

The Firm is representing numerous individuals in GranuFLo lawsuits that allege serious heart injuries due to GranuFlo and NaturaLyte dialysis drugs.

New York, New York (PRWEB) January 24, 2014

GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed in the wake of the 2012 recall of GranuFlo and NaturaLyte dialysis drugs continue to mount in courts around the country, Bernstein Liebhard LLP reports. According to court documents, one of the most recent claims was filed in the U.S. District Court, Northern District of Texas by the family of a woman who died as result of metabolic alkalosis and cardiac arrest, which the complaint alleges were caused by the administration of GranuFlo. Among other things, the dialysis lawsuit claims that prior to the GranuFlo recall, Fresenius Medical Care had reason to believe GranuFlo and NaturaLyte were associated with a risk of metabolic alkalosis, but failed to provide adequate warnings regarding this danger. (Case No. 3:13-cv-05065-B)

“Our Firm is representing numerous clients in GranuFlo lawsuits which echo the allegations being put forth in this complaint,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the GranuFlo recall.

GranuFlo Recall

This case is just one of hundreds of lawsuits filed in courts around the country since the GranuFlo recall was announced. According to court documents, more than 460 dialysis lawsuits naming Fresenius Medical Care have been consolidated in federal multidistrict litigation underway in U.S. District Court, District of Massachusetts. All of those claims similarly allege that that the company failed to provide adequate warnings regarding the use of GranuFlo and NaturaLyte, and continued to aggressively market both products after their risks became apparent in order to protect their market share. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

Additional dialysis lawsuits against Fresenius Medical Care have been consolidated at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)

The GranuFlo recall was announced by the U.S. Food & Drug Administration (FDA) following an Urgent Product Notification issued by Fresenius Medical Care in March 2012, which warned that GranuFlo and NaturaLyte could cause rapid and unsafe elevation of bicarbonate. This occurrence results in metabolic alkalosis, a condition associated with a substantially increased risk of cardiopulmonary arrest and death in dialysis patients. In June of that year, the FDA designated the notification a Class I recall, its most serious type of recall. A Class I recall indicates that use of a medical product could cause serious injury or death.

June 2012, The New York Times reported that the FDA had begun to investigate Fresenius Medical Care’s handling of the GranuFlo recall, after learning that the company had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. However, nothing was done at that time to notify thousands of dialysis centers outside the Fresenius network about the potential dangers associated with the products.*

Individuals who suffered heart attacks, strokes, cardiac arrest, or sudden cardiac death within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to file their own GranuFlo lawsuit. To learn more about the GranuFlo recall, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For more information, and to arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this

advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.thegranuflolawsuit.com/

https://plus.google.com/115936073311125306742?rel=author

For the original version on PRWeb visit: http://www.prweb.com/releases/granuflo-lawsuit/dialysis-lawsuit/prweb11521017.htm


Source: prweb



comments powered by Disqus